USP28 and neoplasm: It will also be interesting to investigate whether combinatorial treatment using the more selective USP28 inhibitors that are currently under pre-clinical evaluation [17] together with some of the established therapeutics targeting MVP activity [56] could exacerbate the induction of inflammation and stress signalling, resulting in improved anti-tumour effects.